MRA with FDA: Two new States accepted
Recommendation
26/27 June 2025
Barcelona, Spain
Supervision of the Pharmaceutical Supply Chain: Challenges and Opportunities
Register now for ECA's GMP Newsletter
After a positive assessment, the US Food and Drug Administration (FDA) has approved Lithuania and Ireland to be fully covered by the current EU-FDA Mutual Recognition Agreement (MRA) of GMP inspections of human manufacturers. They are now also "recognised as capable to carry out good manufacturing practice (GMP) with regard to inspections of sites that manufacture human medicines".
The total number of countries accepted by the FDA is now 14: Austria, Croatia, France, Italy, Malta, Spain, Sweden, United Kingdom, Czech Republic, Greece, Hungary, Romania plus Lithuania and Ireland.
Other EU member states will be added as their evaluation is completed by the US. According to an older EMA press release, "Plans for the agreement to be operational in all EU Member States by 15 July 2019 are on track."
Related GMP News
21.05.2025More FDA Warning Letters citing Quality Oversight
21.05.2025New Version of GMP Auditors Handbook available
21.05.2025FDA: more unannounced Inspections also outside the US
14.05.2025How does FDA train and guide its Inspectors?
30.04.2025QP Declaration: New Q&As published
19.03.2025Root Cause Analysis: Again, problems discovered in GMP-Inspections